Home Cart Sign in  
Chemical Structure| 1359993-59-1 Chemical Structure| 1359993-59-1

Structure of Telratolimod
CAS No.: 1359993-59-1

Chemical Structure| 1359993-59-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MEDI9197 is an imidazoquinoline analogue toll-like receptor (TLR) agonist that can be used for cancer immunotherapy based on its efficacy toward a variety of tumors.

Synonyms: 3M-052; Medi9197

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Telratolimod

CAS No. :1359993-59-1
Formula : C36H59N5O2
M.W : 593.89
SMILES Code : CCCCCCCCCCCCCCCCCC(NCCCCON1C(CCCC)=NC2=C1C3=CC=CC=C3N=C2N)=O
Synonyms :
3M-052; Medi9197
MDL No. :MFCD31692360
InChI Key :RRTPWQXEERTRRK-UHFFFAOYSA-N
Pubchem ID :56833311

Safety of Telratolimod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Telratolimod

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages 100 nM Promoted M1 polarization of macrophages and significantly decreased the subset of M2 macrophages. PMC9929126
Human newborn and adult leukocytes 0.01, 0.1, 1, 10, 100 μM 6 h 3M-052 alone or in combination with PCV13 significantly induced TNF and IFN-γ production in both newborn and adult blood, with synergistic effects when combined with PCV13. PMC5360187

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice B16F10 melanoma model Intratumoral injection 0.2 mg/kg Injected on day 0 and day 3 Suppressed local tumor growth, increased M1 macrophages, and improved CD8+ T cell-mediated immune responses. PMC9929126
Rhesus macaques SARS-CoV-2 infection model Intramuscular injection 10 μg 3 immunizations, 4 and 5 weeks apart To evaluate the immunogenicity and protective efficacy of the RBD + 3M-052-alum vaccine in rhesus macaques, showing that the vaccine induced stronger antibody and T cell responses and significantly reduced viral load after SARS-CoV-2 challenge. PMC9119307
Rhesus macaques Rhesus macaque model Subcutaneous injection 750μg, 75μg Immunizations at weeks 0, 6, 12, and 18, lasting up to 70 weeks The 3M-052 adjuvant significantly enhanced the magnitude and durability of HIV-1 Env-specific antibody responses, particularly inducing durable Env-specific LLPCs in the bone marrow. PMC8109745
Rhesus macaques Neonatal rhesus macaques Intramuscular injection 0.1 mg/kg Single dose at birth 3M-052 significantly accelerated and enhanced neonatal B and T cell immune responses, rapidly exceeding protective antibody levels after a single dose. PMC5360187

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.42mL

1.68mL

0.84mL

16.84mL

3.37mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories